928 related articles for article (PubMed ID: 33268566)
1. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
[TBL] [Abstract][Full Text] [Related]
2. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic significance of combined detection of Epstein-Barr virus antibodies, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma.
Cai YL; Li J; Lu AY; Zheng YM; Zhong WM; Wang W; Gao JQ; Zeng H; Cheng JR; Tang MZ
Asian Pac J Cancer Prev; 2014; 15(5):2001-6. PubMed ID: 24716925
[TBL] [Abstract][Full Text] [Related]
4. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
[TBL] [Abstract][Full Text] [Related]
5. [Six anti-Epstein-Barr virus antibodies in healthy adults in a high risk area of nasopharyngeal carcinoma].
Yi B; Gu YL; Zong YS; Cheng WM; Ji MF
Ai Zheng; 2009 Aug; 28(8):822-6. PubMed ID: 19664327
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
Guo J; Cui Z; Zheng Y; Li X; Chen Y
Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
[TBL] [Abstract][Full Text] [Related]
7. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum.
Cheng WM; Chan KH; Chen HL; Luo RX; Ng SP; Luk W; Zheng BJ; Ji MF; Liang JS; Sham JS; Wang DK; Zong YS; Ng MH
Int J Cancer; 2002 Feb; 97(4):489-92. PubMed ID: 11802211
[TBL] [Abstract][Full Text] [Related]
8. Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: A mediation analysis.
Hsu WL; Chien YC; Huang YT; Yu KJ; Ko JY; Lin CY; Tsou YA; Leu YS; Liao LJ; Chang YL; Su JY; Liu Z; Wang CP; Terng SD; Hua CH; Lee JC; Yang TL; Kate Hsiao CH; Wu MS; Tsai MH; Liu MJ; Lou PJ; Hildesheim A; Chen CJ;
Cancer Med; 2020 Mar; 9(5):1867-1876. PubMed ID: 31925935
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
Zhang WR; Du YY; Guo CY; Zhou HX; Lin JY; Meng XH; Mo HY; Luo DH
Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
[TBL] [Abstract][Full Text] [Related]
10. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
Perez EM; Foley J; Tison T; Silva R; Ogembo JG
Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
[TBL] [Abstract][Full Text] [Related]
11. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
Zheng XH; Lu LX; Li XZ; Jia WH
Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
[TBL] [Abstract][Full Text] [Related]
12. Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.
Bu W; Joyce MG; Nguyen H; Banh DV; Aguilar F; Tariq Z; Yap ML; Tsujimura Y; Gillespie RA; Tsybovsky Y; Andrews SF; Narpala SR; McDermott AB; Rossmann MG; Yasutomi Y; Nabel GJ; Kanekiyo M; Cohen JI
Immunity; 2019 May; 50(5):1305-1316.e6. PubMed ID: 30979688
[TBL] [Abstract][Full Text] [Related]
13. [Detection of serum Epstein-Barr virus antibody level by ELISA in normal populations and nasopharyngeal carcinoma patients in Zhongshan City of China].
Cheng MT; Cheng WM; Ji MF; Liang JS
Di Yi Jun Yi Da Xue Xue Bao; 2002 Sep; 22(9):817-8, 822. PubMed ID: 12297441
[TBL] [Abstract][Full Text] [Related]
14. Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects.
Fachiroh J; Schouten T; Hariwiyanto B; Paramita DK; Harijadi A; Haryana SM; Ng MH; Middeldorp JM
J Infect Dis; 2004 Jul; 190(1):53-62. PubMed ID: 15195243
[TBL] [Abstract][Full Text] [Related]
15. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
[TBL] [Abstract][Full Text] [Related]
16. The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases.
Xu J; Ahmad A; Blagdon M; D'Addario M; Jones JF; Dolcetti R; Vaccher E; Prasad U; Menezes J
Int J Cancer; 1998 Oct; 79(5):481-6. PubMed ID: 9761116
[TBL] [Abstract][Full Text] [Related]
17. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma.
Chan KH; Gu YL; Ng F; Ng PS; Seto WH; Sham JS; Chua D; Wei W; Chen YL; Luk W; Zong YS; Ng MH
Int J Cancer; 2003 Jul; 105(5):706-9. PubMed ID: 12740922
[TBL] [Abstract][Full Text] [Related]
18. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.
Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM
Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087
[TBL] [Abstract][Full Text] [Related]
19. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
Front Immunol; 2018; 9():932. PubMed ID: 29765376
[TBL] [Abstract][Full Text] [Related]
20. Proper use of serum antibody titres against Epstein-Barr virus in nasopharyngeal carcinoma: IgA/virus capsid antigen for diagnosis and EBV-related nuclear antigen-2 for follow-up.
Shimakage M; Dezawa T; Chatani M
Acta Otolaryngol; 2000 Jan; 120(1):100-4. PubMed ID: 10779195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
